Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationPillar 3 · inherited risk, for you and your family
Heritage
Where Signature reads the tumour, Heritage reads you: the inherited changes that can raise cancer risk for you and your blood relatives.
01Inherited risk
Where Signature reads the tumour, Heritage reads you
Heritage looks at the inherited changes you were born with, the ones that can raise cancer risk for you and your blood relatives.
Is this part of a pattern the family should know about?
Image placeholder
Three generations of one family
02
Why it matters
For you
An inherited change can shape treatment, because some cancers with germline changes respond to specific drugs. It also shapes future screening.
For your family
Finding a variant lets relatives choose testing, earlier screening and prevention. One test can protect a whole family.
For prevention
Knowing risk in advance turns cancer care from reactive to proactive.
03
The two tests
| Heritage Core | Heritage Adhoc | |
|---|---|---|
| What it is | A broad hereditary-cancer panel | A focused test for one known variant |
| Best when | You want a full inherited-risk assessment | A family variant is already known |
| Who it helps | You, and through you your family | Relatives of someone with a known variant |
| Price | ₹50,000 index test | ₹35,000 per family member |
04
Counselling is included
No result without support.
Inherited risk is sensitive. It touches family, children and difficult feelings. Every Heritage test includes genetic counselling through KPCIRC, before and after: to help you decide what you want to know, to explain results plainly, and to plan next steps.
You are never handed a life-changing result and left alone with it.
Video placeholder
What a genetic counselling session is actually like
05
Pricing
₹50,000 index test, then ₹35,000 per family member
Cascade testing for relatives checks for the specific variant found, so it is more focused and costs less. Confirmed at your consultation, with counselling included.
10.3%of cancer patients carried an inherited variant in a large study
~50%of carriers can be missed by guideline-only criteria
1finding can protect an entire family
Research and evidence
The science behind this
Multi-gene germline panels repeatedly find inherited risk that would otherwise be missed.
Study 1
Inherited risk is common, and often unexpected
Among 10,975 cancer patients tested with a broad germline panel, 10.3% carried a pathogenic variant, and many would not have been predicted from personal or family history alone.
Landry KK, et al. JCO Precision Oncology, 2024.
Study 2
Panels find actionable variants across the board
In a large colorectal cohort, 14.2% carried a pathogenic germline variant, with actionable findings across every age, ancestry and panel size.
Multigene panel study, JCO Precision Oncology, 2022.
Study 3
Guideline criteria miss carriers
When testing is restricted to guideline criteria, roughly half of carriers can be missed, which argues for broader testing.
Beitsch PD, et al. Journal of Clinical Oncology, 2019.
These independent, peer-reviewed studies describe the class of technology we use. They are shared for education. They are not results for any individual and not a promise of benefit.
Being clear about our limits
What we do and do not do
What we DO
- Assess inherited cancer risk for you
- Enable cascade testing to protect blood relatives
- Include KPCIRC genetic counselling before and after
- Flag inherited changes that can shape treatment
What we DON’T do
- Diagnose cancer or read the tumour
- Predict with certainty that a cancer will occur
- Test relatives without their own consent and counselling
- Replace clinical screening or specialist follow-up
Plain-language glossary (6 terms)
| Term | What it means |
|---|---|
| Germline | An inherited change, present from birth and passable to children. |
| Somatic | A change that arises in the tumour during life. Not inherited. |
| Pathogenic variant | A change known to be disease-causing. Here, one that raises cancer risk. |
| VUS | Variant of uncertain significance, a change whose meaning is not yet clear. |
| Penetrance | How likely a carrier is to actually develop the cancer. |
| Cascade testing | Testing blood relatives for a known family variant. |
Important information and regulatory status
Heritage is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner (CAP-accredited, ISO 15189) following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal